Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Psychiatry Research|July 1, 1994
Performance of nonpsychotic relatives of schizophrenic patients on cognitive testsR S Keefe, J M Silverman, S E Roitman, et al.
Frontiers in Neurology|August 6, 2020
Efficacy of Tasimelteon (HETLIOZ®) in the Treatment of Jet Lag Disorder Evaluated in an 8-h Phase Advance Model; a Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialChristos M Polymeropoulos, Michael A Mohrman, Madison S Keefe, et al.
Schizophrenia Research|August 27, 2014
Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive BatteryBradley E Gray, Robert P McMahon, Michael F Green, et al.
Psychological Medicine|July 29, 2014
Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relativesS Lui, L Yao, Y Xiao, et al.
Archives of General Psychiatry|February 1, 1997
Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophreniaR S Keefe, J M Silverman, R C Mohs, et al.
Investigative Ophthalmology & Visual Science|May 8, 2000
Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulationL Cheng, K Y Hostetler, S Chaidhawangul, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|July 5, 2001
Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbitL Cheng, M E Rivero, C R Garcia, et al.
AJNR. American Journal of Neuroradiology|February 16, 2023
Validity Assessment of an Automated Brain Morphometry Tool for Patients with De Novo Memory SymptomsF Rahmani, S Jindal, C A Raji, et al.
Schizophrenia Research|March 15, 2006
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episodeDiana O Perkins, Jacqueline L Johnson, Robert M Hamer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Pageof 8